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EDITORIAL
Hepatitis C and renal transplantation: The controversy continues
Hepatitis C virus (HCV) infection, the leading cause of post-
transplant liver disease, has recently been recognized as one of the
major causes of morbidity and mortality in renal transplantation.
Most HCV antibody-positive recipients acquire HCV infection
before or at the time of transplantation. The prevalence of HCV
among patients with end-stage renal disease (ESRD) undergoing
dialysis is reported between 12% to 85%, depending on the
techniques used such as antibody and RNA assays [1–4]. It has
been shown that HCV is transmissible by organ transplantation [5,
6]. In recipients of kidneys from HCV antibody positive donors,
57 to 96% were tested positive for HCV RNA by polymerase
chain reaction (PCR) and 0 to 55% developed post-transplanta-
tion liver disease [7].
There have been controversial reports on the long-term effects
of HCV infection on graft and patient survival in kidney trans-
plant recipients. In this issue of Kidney International, Pereira and
colleagues analyze the impact of HCV infection on survival of
kidney transplant and ESRD patients [8]. They report that the
presence of HCV infection was associated with an increased risk
of death in patients referred for renal transplantation, and the
effect of transplantation was similar in anti-HCV positive and
negative patients. They conclude that anti-HCV positive status is
not a contraindication for renal transplantation, which has a
beneficial effect on long-term survival in anti-HCV positive
patients.
The report by Pereira and associates provides new fuel to the
controversy as to how HCV infection alters outcomes in ESRD
and transplant population [8]. Two important infection-related
outcomes are described by the authors: the relationship of infec-
tion to chronic liver disease and to transplant outcome. There
have been other reports of progressive liver disease in HCV-
infected renal allograft recipients. A study by Morales et al
demonstrated that more than 50% of HCV positive renal trans-
plant recipients exhibited a severe pattern including cirrhosis,
chronic active hepatitis and chronic persistent hepatitis in liver
biopsies indicating the seriousness of HCV infection [9]. Older
age at transplant, female sex, and morphologic diagnosis of
advanced chronic hepatitis were found to be associated with
histologic progression to cirrhosis [10].
On the other hand, several other groups have described the
absence of dire consequences of HCV infection on patient and
graft survival in renal allograft recipients [11, 12]. A group of
HCV-infected ESRD patients (N 5 14) was prospectively fol-
lowed for up to two years with pretransplant liver biopsies, and
virologic and biochemical parameters post-transplant [11]. All
patients did well with functioning grafts despite enhanced viral
replication and mild increase in liver enzymes. Haem and col-
leagues followed 62 HCV positive renal transplant recipients with
liver biopsies for a mean of 72 months (range 36 to 108 months)
[12]. Although they found a 42% incidence of chronic active
hepatitis, patient and graft survival were not significantly different
from HCV negative recipients. At our institution, we found that,
despite a predisposition to post-transplant liver disease in recipi-
ents with pre-existing HCV infection, overall patient and graft
survival were similar in long-term follow up (median follow-up 9
years) in the HCV positive and HCV negative recipients [12].
Irrespective of the antibody status, the outcome was poor in
patients with associated liver disease.
Less controversial has been the variant impact of HCV infec-
tion on patient outcomes related to forms of renal replacement.
Similar to the report by Pereira et al, in a study by Knoll and
colleagues, HCV-positive renal transplant recipients had a better
survival compared with HCV-positive patients who were accept-
able candidates for transplantation but were on dialysis [14]. The
importance of these studies lies in using a cohort of dialysis
patients for outcome comparison very similar to the transplant
group as they were on the transplant waiting list, reducing the
possibility that differences discerned were merely a consequence
of selection bias.
The continuing controversy of the impact of HCV infection on
the transplant recipient demands further study and analysis by
examining such issues as variant viral strains or geographic
differences, and improving our understanding of HCV related
liver disease. Nevertheless, the report by Pereira and his col-
leagues supports the conclusion that transplantation is the pre-
ferred mode of renal replacement therapy for HCV positive
patients with end-stage renal disease [8].
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